[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy). The objective of this study was to investigate the long-term health economic consequences of this treatment strategy in a Swiss health care setting. This analysis used a Markov model to simulate the progression of nephropathy, life-years and treatment costs over ten years for each of the three treatment options. In additon, sensitivity analyses were performed. Treatment with irbesartan will save CHF 22681/patient as compared with amlodipine and CHF 13847 as compared with standard therapy.
Frei
A
A
Gesundheitsökonomische Studien und Beratung, Pratteln. afrei.gsb@bluewin.ch
Palmer
A J
AJ
Burnier
M
M
Hess
B
B
D017311:Amlodipine / Q000191:economics / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000191:economics / Q000627:therapeutic use; D015331:Cohort Studies; D017046:Cost Savings; D003365:Costs and Cost Analysis; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000191:economics*; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality / Q000601:surgery; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics* / Q000209:etiology; D000077405:Irbesartan; D007676:Kidney Failure, Chronic / Q000209:etiology; D016030:Kidney Transplantation / Q000191:economics; D008390:Markov Chains; D015337:Multicenter Studies as Topic; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D006435:Renal Dialysis; D012306:Risk; D012680:Sensitivity and Specificity; D013557:Switzerland; D013777:Tetrazoles / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D013997:Time Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D002121:Calcium Channel Blockers; D010919:Placebos; D013777:Tetrazoles; D017311:Amlodipine; D000077405:Irbesartan